LONDON (ShareCast) - (Sharecast News) - Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by surging demand for its diabetes drug Mounjaro and weight-loss treatment Zepbound.
Eli Lilly said revenues jumped 54% year-on-year to $17.6bn, with US sales up 45% to $11.3bn, driven by a 60% increase in prescription volumes. Net income rose to $5.58bn, or $6.21 per share, from $970m a year earlier, while adjusted earnings came in at $7.02 per share.

Mounjaro generated $6.52bn in revenue, up 109% and well ahead of forecasts, while Zepbound rose 184% to $3.59bn, slightly beating expectations.

Eli Lilly also raised its full-year guidance, with the firm now expecting revenue to be between $63bn and $63.5bn and adjusted profits to be $23-$23.70 per share. It also noted that its outlook reflects current US tariffs, but excluded potential new levies on imported pharmaceuticals.

As of 1430 GMT, Eli Lilly shares were up 0.85% at $820.45 each.





Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE